Conference Correspondent

Beth Faiman discusses why it's important to communicate with and educate patients so that they can better manage their symptoms before they become more severe.
Beth Faiman expresses her main concerns regarding new treatments being studied to treat multiple myeloma.
Beth Faiman identifies how the Janssen CarePath program can financially help anyone who is diagnosed with multiple myeloma and requires daratumumab.
As patients with multiple myeloma are now living longer, survivorship care is becoming more crucial.
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments.
Leslie Lauersdorf discusses the need to balance optimism and realism in caring for patients with relapsed/refractory multiple myeloma.
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.
Leslie Lauersdorf believes patient education is important in both newly diagnosed pateints with multiple myeloma or patients with relapsed/refractory disease to help them understand their disease and the different treatment options.
Leslie Lauersdorf notes that having patients assist in managing their own side effects is important to help them stay on treatment and improve their quality of life.
Leslie Lauersdorf is excited by the prospect of new mutliple myeloma therapies, and notes that finding the best sequence for each patient is key.
Page 4 of 42
Results 31 - 40 of 412